
Nicholas DeVito/LinkedIn
Apr 22, 2025, 14:05
Nicholas DeVito: Duke’s first-line immunotherapy trial for advanced/metastatic CRC is still enrolling
Nicholas DeVito, Assistant Professor of Medicine at the Division of Medical Oncology at Duke University, shared a post on LinkedIn:
“Our first-line immunotherapy (botensilimab/balstilimab) trial for advanced/metastatic colorectal cancer without liver, bone, or brain metastasis is still enrolling!
This trial is supported by Gateway for Cancer Research, Duke CRUSH CRC, and patient philanthropy.
Learn more about the BBOpCo trial here.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 11, 2025, 10:32
May 11, 2025, 10:23
May 11, 2025, 09:27
May 11, 2025, 09:19
May 11, 2025, 09:13